Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis

Abstract Background Bladder cancer is one of the top 10 cancers diagnosed in Americans with a median age of 73. This is the patient population that tends to be older with multiple medical conditions, and previously described variability in treatment in the earlier stages of the disease. This study a...

Full description

Bibliographic Details
Main Authors: Elizabeth R. Kessler, Sarah J. Schmiege, Megan Eguchi, Sarguni Singh, Stacy M. Fischer
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Aging and Cancer
Subjects:
Online Access:https://doi.org/10.1002/aac2.12048
_version_ 1818097269194358784
author Elizabeth R. Kessler
Sarah J. Schmiege
Megan Eguchi
Sarguni Singh
Stacy M. Fischer
author_facet Elizabeth R. Kessler
Sarah J. Schmiege
Megan Eguchi
Sarguni Singh
Stacy M. Fischer
author_sort Elizabeth R. Kessler
collection DOAJ
description Abstract Background Bladder cancer is one of the top 10 cancers diagnosed in Americans with a median age of 73. This is the patient population that tends to be older with multiple medical conditions, and previously described variability in treatment in the earlier stages of the disease. This study aimed to evaluate the first‐line therapeutic choices for older adults newly diagnosed with advanced bladder cancer. In addition, this work evaluated predictors of response as well as the role of events of functional importance in relation to treatment assignment. Methods A population‐based cohort study was conducted using the SEER‐Medicare database of patients with advanced stage bladder cancer not eligible for curative intent therapy between 2010 and 2013. Patient groups of interest were compared via univariate and multivariate associations. Additionally, a latent class analysis was applied to identify classes with similar features in reference to events of functional importance—events linked to the maintenance or improvement of physical function status. Results Within the sample, we noted that a minority of patients received a standard cisplatin‐containing regimen (14.77%) and a majority did not receive any chemotherapy (59.69%). Most patients were over age 75. The adjusted odds ratio of no chemo versus cisplatin in patients aged 76 and older compared to patients 66–75 was 6.61 (4.79–9.13; p < 0.0001). We applied latent class analysis methods to the dataset, and three classes demonstrated very low and moderate levels of functional events in the 12 months prior to a person's first outpatient visit for advanced bladder cancer care. Conclusions Patients with new diagnosis of advanced bladder cancer largely do not receive the recommended first‐line systemic therapy of cisplatin chemotherapy, and a significant majority does not receive any treatment. When evaluating the association between class assignment and predictors of chemotherapy use, such as comorbidity and age, patients with “low usage overall” were more likely to receive chemotherapy. Yet even patients who received chemotherapy had some events of functional importance.
first_indexed 2024-12-10T23:17:50Z
format Article
id doaj.art-a68e19d236f844029143462d1cdb1b04
institution Directory Open Access Journal
issn 2643-8909
language English
last_indexed 2024-12-10T23:17:50Z
publishDate 2022-06-01
publisher Wiley
record_format Article
series Aging and Cancer
spelling doaj.art-a68e19d236f844029143462d1cdb1b042022-12-22T01:29:48ZengWileyAging and Cancer2643-89092022-06-013210511510.1002/aac2.12048Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysisElizabeth R. Kessler0Sarah J. Schmiege1Megan Eguchi2Sarguni Singh3Stacy M. Fischer4Department of Medicine Division of Medical Oncology University of Colorado School of Medicine Aurora Colorado USADepartment of Biostatistics & Informatics, Center for Innovative Design & Analysis Colorado School of Public Health Aurora Colorado USADepartment of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles California USADepartment of Medicine Division of Hospital Medicine University of Colorado School of Medicine Aurora Colorado USADepartment of Medicine Division of General Internal Medicine University of Colorado School of Medicine Aurora Colorado USAAbstract Background Bladder cancer is one of the top 10 cancers diagnosed in Americans with a median age of 73. This is the patient population that tends to be older with multiple medical conditions, and previously described variability in treatment in the earlier stages of the disease. This study aimed to evaluate the first‐line therapeutic choices for older adults newly diagnosed with advanced bladder cancer. In addition, this work evaluated predictors of response as well as the role of events of functional importance in relation to treatment assignment. Methods A population‐based cohort study was conducted using the SEER‐Medicare database of patients with advanced stage bladder cancer not eligible for curative intent therapy between 2010 and 2013. Patient groups of interest were compared via univariate and multivariate associations. Additionally, a latent class analysis was applied to identify classes with similar features in reference to events of functional importance—events linked to the maintenance or improvement of physical function status. Results Within the sample, we noted that a minority of patients received a standard cisplatin‐containing regimen (14.77%) and a majority did not receive any chemotherapy (59.69%). Most patients were over age 75. The adjusted odds ratio of no chemo versus cisplatin in patients aged 76 and older compared to patients 66–75 was 6.61 (4.79–9.13; p < 0.0001). We applied latent class analysis methods to the dataset, and three classes demonstrated very low and moderate levels of functional events in the 12 months prior to a person's first outpatient visit for advanced bladder cancer care. Conclusions Patients with new diagnosis of advanced bladder cancer largely do not receive the recommended first‐line systemic therapy of cisplatin chemotherapy, and a significant majority does not receive any treatment. When evaluating the association between class assignment and predictors of chemotherapy use, such as comorbidity and age, patients with “low usage overall” were more likely to receive chemotherapy. Yet even patients who received chemotherapy had some events of functional importance.https://doi.org/10.1002/aac2.12048agingbladder cancercancer carefunctional status
spellingShingle Elizabeth R. Kessler
Sarah J. Schmiege
Megan Eguchi
Sarguni Singh
Stacy M. Fischer
Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis
Aging and Cancer
aging
bladder cancer
cancer care
functional status
title Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis
title_full Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis
title_fullStr Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis
title_full_unstemmed Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis
title_short Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis
title_sort patterns of treatment in older patients with newly diagnosed advanced bladder cancer a seer dataset analysis
topic aging
bladder cancer
cancer care
functional status
url https://doi.org/10.1002/aac2.12048
work_keys_str_mv AT elizabethrkessler patternsoftreatmentinolderpatientswithnewlydiagnosedadvancedbladdercanceraseerdatasetanalysis
AT sarahjschmiege patternsoftreatmentinolderpatientswithnewlydiagnosedadvancedbladdercanceraseerdatasetanalysis
AT meganeguchi patternsoftreatmentinolderpatientswithnewlydiagnosedadvancedbladdercanceraseerdatasetanalysis
AT sargunisingh patternsoftreatmentinolderpatientswithnewlydiagnosedadvancedbladdercanceraseerdatasetanalysis
AT stacymfischer patternsoftreatmentinolderpatientswithnewlydiagnosedadvancedbladdercanceraseerdatasetanalysis